New 'Sandwich' therapy aims to control leukemia with fewer risks
NCT ID NCT06507514
Summary
This study is testing a new treatment approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a standard donor stem cell transplant. Researchers are combining an immunotherapy drug called blinatumomab with a transplant using the patient's own stem cells. The goal is to control the leukemia while reducing the serious risks associated with donor transplants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.